
HLUKF
Healthcare · Drug Manufacturers - Specialty & Generic · $4.92B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 11, 2022 | Before the open | 2.84 | 4.67 | +64.4% |
| Feb 9, 2022 | Before the open | 1.61 | 2.09 | +29.8% |
| Nov 10, 2021 | Before the open | 1.66 | 2.78 | +67.5% |
| Sep 30, 2021 | Time not confirmed | 1.86 | 0.25 | -86.5% |
| Jun 30, 2021 | Time not confirmed | 2.60 | 0.30 | -88.3% |
| Mar 31, 2021 | Time not confirmed | 0.04 | 0.49 | +1131.8% |
| Dec 31, 2020 | Time not confirmed | 2.03 | 0.31 | -84.7% |
| Sep 30, 2020 | Time not confirmed | 1.95 | 0.33 | -83.2% |
| Jun 30, 2020 | Time not confirmed | 2.42 | 0.40 | -83.6% |
| Mar 31, 2020 | Time not confirmed | 0.57 | 0.07 | -88.1% |
| Dec 31, 2019 | Time not confirmed | 4.00 | -0.09 | -102.4% |
| Sep 30, 2019 | Time not confirmed | 4.33 | 0.55 | -87.3% |
| Jun 30, 2019 | Time not confirmed | 4.22 |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic…
| 0.60 |
| -85.7% |
| Mar 31, 2019 | Time not confirmed | 3.30 | 0.68 | -79.4% |
| Dec 31, 2018 | Time not confirmed | 5.33 | 0.51 | -90.5% |
| Sep 30, 2018 | Time not confirmed | 4.78 | 0.83 | -82.7% |
| Jun 30, 2018 | Time not confirmed | 4.52 | 0.79 | -82.6% |
| Mar 31, 2018 | Time not confirmed | 3.38 | 1.00 | -70.5% |